Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Oral salmon calcitonin, salmon calcitonin nasal spray, Oral salmon calcitonin, salmon calcitonin
salmon calcitonin, salmon calcitonin · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Oral salmon calcitonin, salmon calcitonin nasal spray | DRUG | - |
| Oral salmon calcitonin | DRUG | - |
Inclusion Criteria: * Medical history and symptoms of knee osteoarthritis Exclusion Criteria: * Any other disease or medication affecting the bone or cartilage. * Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering t...
Top 5 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 3 | PHASE3 | Eloralintide and Tirzepatide, Orforglipron, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Salmon calcitonin is being studied for osteoarthritis and postmenopausal osteoporosis. It is an investigational therapy in Phase 1 clinical development, and the completed trials evaluated its pharmacokinetics and pharmacodynamics in patients with osteoarthritis and in healthy postmenopausal women.
Salmon calcitonin is an agonist of CALCR, the calcitonin receptor. By binding to and activating this receptor, it mimics the action of endogenous calcitonin, which regulates calcium homeostasis and bone metabolism. This mechanism underlies its investigation in musculoskeletal conditions such as osteoarthritis and postmenopausal osteoporosis.
Salmon calcitonin is being developed by Novartis AG, which trades under the ticker NVS. The company is responsible for the clinical program evaluating the drug in osteoarthritis and postmenopausal osteoporosis.
Salmon calcitonin is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any indication. The program includes completed Phase 1 trials, and no active trials are currently listed.
Salmon calcitonin has been evaluated in completed Phase 1 trials, including NCT00486317 in patients with osteoarthritis, and NCT00411125 and NCT00395395 in healthy postmenopausal women. These studies assessed pharmacokinetics and pharmacodynamics, with the latter two also examining effects of water and food intake.
Yes, oral salmon calcitonin and salmon calcitonin nasal spray are alternative names or formulations of salmon calcitonin. The drug is also known by these terms, which refer to different routes of administration of the same active substance.